184 related articles for article (PubMed ID: 11079678)
1. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.
Yang Z; Kozai T; van der Loo B; Viswambharan H; Lachat M; Turina MI; Malinski T; Lüscher TF
J Am Coll Cardiol; 2000 Nov; 36(5):1691-7. PubMed ID: 11079678
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway.
Yamamoto T; Takeda K; Harada S; Nakata T; Azuma A; Sasaki S; Nakagawa M
Atherosclerosis; 2003 Feb; 166(2):213-22. PubMed ID: 12535733
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
[TBL] [Abstract][Full Text] [Related]
4. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway.
Kozai T; Eto M; Yang Z; Shimokawa H; Lüscher TF
Cardiovasc Res; 2005 Dec; 68(3):475-82. PubMed ID: 16098957
[TBL] [Abstract][Full Text] [Related]
5. Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.
Kalinowski L; Dobrucki IT; Malinski T
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):585-95. PubMed ID: 12512694
[TBL] [Abstract][Full Text] [Related]
6. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
7. The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.
Berkels R; Nouri SK; Taubert D; Bartels H; Roesen P; Roesen R; Klaus W
J Cardiovasc Pharmacol; 2003 Sep; 42(3):356-63. PubMed ID: 12960680
[TBL] [Abstract][Full Text] [Related]
8. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures.
Axel DI; Riessen R; Runge H; Viebahn R; Karsch KR
J Cardiovasc Pharmacol; 2000 Apr; 35(4):619-29. PubMed ID: 10774794
[TBL] [Abstract][Full Text] [Related]
9. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.
Kalinowski L; Dobrucki LW; Brovkovych V; Malinski T
Circulation; 2002 Feb; 105(8):933-8. PubMed ID: 11864921
[TBL] [Abstract][Full Text] [Related]
10. Cerivastatin activates endothelial calcium-activated potassium channels and thereby modulates endothelial nitric oxide production and cell proliferation.
Kuhlmann CR; Gast C; Li F; Schäfer M; Tillmanns H; Waldecker B; Wiecha J
J Am Soc Nephrol; 2004 Apr; 15(4):868-75. PubMed ID: 15034088
[TBL] [Abstract][Full Text] [Related]
11. Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.
González-Fernández F; Jiménez A; López-Blaya A; Velasco S; Arriero MM; Celdrán A; Rico L; Farré J; Casado S; López-Farré A
Atherosclerosis; 2001 Mar; 155(1):61-70. PubMed ID: 11223427
[TBL] [Abstract][Full Text] [Related]
12. Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Wajima T; Makita S; Oshima K
Clin Exp Pharmacol Physiol; 2003 Dec; 30(12):958-62. PubMed ID: 14678236
[TBL] [Abstract][Full Text] [Related]
13. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
Corsini A; Arnaboldi L; Raiteri M; Quarato P; Faggiotto A; Paoletti R; Fumagalli R
Pharmacol Res; 1996 Jan; 33(1):55-61. PubMed ID: 8817647
[TBL] [Abstract][Full Text] [Related]
14. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Park JK; Müller DN; Mervaala EM; Dechend R; Fiebeler A; Schmidt F; Bieringer M; Schäfer O; Lindschau C; Schneider W; Ganten D; Luft FC; Haller H
Kidney Int; 2000 Oct; 58(4):1420-30. PubMed ID: 11012877
[TBL] [Abstract][Full Text] [Related]
15. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors.
Yang Z; Oemar BS; Carrel T; Kipfer B; Julmy F; Lüscher TF
Circulation; 1998 Jan; 97(2):181-7. PubMed ID: 9445171
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin, a potent HMG-CoA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro.
Sato I; Ma L; Ikeda M; Morita I; Murota S
J Atheroscler Thromb; 1998; 4(3):102-6. PubMed ID: 9730140
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration.
Porter KE; Naik J; Turner NA; Dickinson T; Thompson MM; London NJ
J Vasc Surg; 2002 Jul; 36(1):150-7. PubMed ID: 12096273
[TBL] [Abstract][Full Text] [Related]
18. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.
Sata M; Nishimatsu H; Suzuki E; Sugiura S; Yoshizumi M; Ouchi Y; Hirata Y; Nagai R
FASEB J; 2001 Nov; 15(13):2530-2. PubMed ID: 11641268
[TBL] [Abstract][Full Text] [Related]
19. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Wagner AH; Köhler T; Rückschloss U; Just I; Hecker M
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):61-9. PubMed ID: 10634801
[TBL] [Abstract][Full Text] [Related]
20. Action of an HMG CoA reductase inhibitor, lovastatin, on apoptosis of untransformed and ts-SV40 transformed human smooth muscle cells derived from saphenous vein.
Unlu S; Clunn G; Schachter M; Demoliou-Mason C; Hughes AD
J Cardiovasc Pharmacol; 2001 Aug; 38(2):161-73. PubMed ID: 11483865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
